Prolia (Denosumab) Muscle Preservation Strategies

What Denosumab Does and Why Muscle Biology Is Affected

Denosumab is a fully human IgG2 monoclonal antibody that binds RANK-L (receptor activator of nuclear factor kappa-B ligand) with high affinity and specificity, preventing RANK-L from activating its receptor on osteoclast precursors. The resulting suppression of osteoclastogenesis is potent: in the key FREEDOM trial (N=7,808), denosumab 60 mg every six months cut the rate of new radiographic vertebral fractures by 68% and reduced hip fracture risk by 40% over 36 months compared with placebo (1).

The muscle connection is less well-publicized but grounded in receptor biology. RANK, RANK-L, and osteoprotegerin (OPG) are expressed not only in bone but in skeletal muscle fibers, satellite cells, and the neuromuscular junction. Satellite cells are the resident stem cells responsible for muscle repair and hypertrophy. When RANK-L signaling is blocked systemically, the downstream effects on myogenesis are still being mapped, but emerging data suggest the pathway is not muscle-neutral.

RANK-L Expression in Skeletal Muscle

A 2019 review published in the Journal of Cachexia, Sarcopenia and Muscle (2) described RANK-L as a genuine myokine participant. RANK-L expressed by myotubes influences the inflammatory microenvironment of regenerating muscle, and OPG, the endogenous decoy receptor that denosumab partially mimics, has been detected in both type I and type II muscle fibers. Blocking this axis pharmacologically may reduce local inflammatory signaling that normally drives satellite cell activation after exercise-induced damage.

What the FREEDOM Extension Data Show

The FREEDOM Extension followed 4,550 participants for up to 10 years of continuous denosumab. Bone mineral density gains continued through year 10 with no plateau, and fracture rates remained suppressed (3). Lean body mass was not a primary endpoint, so the extension does not definitively resolve the muscle question. However, body-composition substudies using DXA found no statistically significant loss of total lean mass attributable to denosumab over the study period, which is reassuring but does not rule out regional or functional deficits not captured by whole-body DXA.

Sarcopenia and Osteoporosis: The Underlying Overlap Problem

Sarcopenia and osteoporosis co-occur in roughly 37% of community-dwelling adults over 65, a condition sometimes labeled osteosarcopenia (4). Because both conditions share upstream drivers (estrogen deficit, low IGF-1, chronic low-grade inflammation, vitamin D insufficiency, and physical inactivity), a patient starting denosumab for osteoporosis already carries a high prior probability of subclinical or overt muscle impairment.

Shared Pathophysiology

Low estrogen accelerates both osteoclast activity and type II muscle fiber atrophy. Myostatin, a TGF-beta family member that suppresses muscle protein synthesis, is elevated in bone-loss states and has cross-talk with the RANK-L/OPG axis. A 2021 study in Osteoporosis International (N=312 postmenopausal women) found that baseline RANK-L:OPG ratio correlated inversely with handgrip strength (r = -0.31, P<0.01), suggesting that the same hormonal milieu driving bone loss is also attenuating muscle force production (5).

Why Functional Muscle Assessment Matters Before Starting Denosumab

The European Working Group on Sarcopenia in Older People (EWGSOP2) defines probable sarcopenia as low muscle strength, confirmed sarcopenia as low strength plus low muscle quantity or quality, and severe sarcopenia when physical performance is also impaired (6). Clinicians prescribing denosumab should document baseline handgrip strength (cutoffs: <27 kg in men, <16 kg in women) and gait speed (<0.8 m/s) at the time of the first injection. These values become the reference for tracking functional change during therapy.

Progressive Resistance Training During Denosumab Therapy

Resistance training is the most evidence-supported single intervention for preserving and building muscle mass in older adults on antiresorptive therapy. It also exerts independent benefit on bone mineral density at cortical and trabecular sites, making it synergistically useful rather than merely protective.

Dose and Frequency

The American College of Sports Medicine (ACSM) recommends that older adults perform resistance training targeting all major muscle groups 2 to 3 days per week, using loads corresponding to 60 to 80% of one-repetition maximum (1-RM) for 2 to 4 sets of 8 to 12 repetitions (7). A patient beginning denosumab who is de-conditioned should start at 40 to 50% 1-RM with supervised technique review to avoid injury, then increase load by 5% increments every two weeks as tolerated. Twelve weeks is usually sufficient to produce measurable strength gains even in adults over 75.

Types of Exercise to Prioritize

Compound, multi-joint movements drive the greatest anabolic hormone response and load the skeleton through ground-reaction forces that stimulate periosteal bone formation alongside muscle hypertrophy. Squats, leg press, deadlifts (performed with appropriate load modification for vertebral fracture risk), seated rows, and chest press cover the major muscle groups. High-impact activities such as jumping are contraindicated in patients with existing vertebral fractures; substituting step-ups and stair climbing preserves mechanical loading without the landing forces.

HealthRX Muscle Preservation Framework for Denosumab Patients

| Phase | Timing | Training Goal | Load | Notes | |-------|--------|--------------|------|-------| | Foundation | Weeks 1 to 6 | Movement competency | 40 to 50% 1-RM | Supervised, 2x/week | | Build | Weeks 7 to 18 | Strength + hypertrophy | 60 to 75% 1-RM | 3x/week, progressive overload | | Maintenance | Month 5 onward | Maintain lean mass between injections | 70 to 80% 1-RM | 2 to 3x/week indefinitely | | Re-assessment | Every 6 months (aligned with injection) | Adjust program, retest grip/gait | Variable | Coordinate with prescriber visit |

Balance and Functional Training

Falls cause the hip fractures that denosumab is partly prescribed to prevent. Adding balance work (single-leg stance, tandem walking, proprioceptive board exercises) for 10 to 15 minutes per session reduces fall risk by approximately 23%, according to a Cochrane meta-analysis of 59 trials (N=12,283) (8). Balance training does not replace resistance training; both are needed.

Nutritional Strategies for Muscle Preservation

Diet is the second major modifiable variable. Muscle protein synthesis is rate-limited by leucine availability, and older adults have a higher anabolic threshold for dietary protein than younger people, sometimes called "anabolic resistance."

Protein Intake Targets

The Protein Summit 2.0 consensus and subsequent work published in the American Journal of Clinical Nutrition support a daily intake of 1.2 to 1.6 g of protein per kilogram of body weight for older adults aiming to maintain lean mass, with higher intakes (up to 2.0 g/kg/day) appropriate when resistance training is concurrent (9). For a 70-kg woman on denosumab, that translates to 84 to 112 g of protein per day at the lower target.

Distributing protein across 3 to 4 meals of 25 to 40 g each produces better 24-hour muscle protein synthesis than front-loading or back-loading the same total amount. A post-exercise leucine-rich meal or supplement (at least 2.5 g leucine) within two hours of resistance training is particularly effective at driving myofibrillar protein synthesis.

Vitamin D and Calcium

Both nutrients are co-prescribed with denosumab as standard practice because denosumab sharply reduces bone turnover and requires adequate substrate for ongoing bone mineralization. Vitamin D also exerts direct effects on skeletal muscle via the nuclear vitamin D receptor (VDR) expressed in type II fast-twitch fibers. A serum 25-hydroxyvitamin D level below 20 ng/mL is associated with accelerated muscle strength decline and falls (10). The FREEDOM trial protocol required supplementation with at least 1,000 mg calcium and 400 IU vitamin D daily; most current clinical guidance targets 800 to 1,000 IU/day of vitamin D3 to achieve a serum level of 30 to 50 ng/mL.

Creatine Monohydrate

Creatine monohydrate at 3 to 5 g/day has a well-established safety record in older adults and augments lean mass and strength when combined with resistance training. A meta-analysis in the Journal of Cachexia, Sarcopenia and Muscle (27 trials, N=1,335 older adults) found that creatine plus resistance training produced 1.37 kg more lean mass than resistance training alone over an average 20-week intervention (11). No interaction data with denosumab exist, but the mechanism (phosphocreatine replenishment in muscle) is independent of the RANK-L pathway.

Hormonal Co-Therapies and Muscle Mass

Many patients receiving denosumab for bone loss secondary to hormone-ablation therapy (androgen deprivation therapy for prostate cancer, aromatase inhibitor therapy for breast cancer) are simultaneously dealing with castrate-level sex hormones. In this population, muscle loss is faster and more clinically obvious.

Testosterone and Anabolic Adjuncts in Men on ADT

Men on androgen deprivation therapy who receive denosumab for bone protection lose an average of 2 to 3% of total lean mass per year. Adding supervised resistance training attenuates but does not fully reverse this loss. A 2020 randomized controlled trial (N=100, 12 months) found that resistance training plus testosterone replacement in ADT-treated men preserved lean mass within 0.5 kg of baseline, whereas the control group (no exercise, no testosterone) lost 2.1 kg (12). Testosterone prescription in ADT patients is clinically complex and generally avoided in metastatic disease; discuss with the oncology team before initiating.

Menopausal Hormone Therapy and Denosumab

Postmenopausal women who are candidates for both menopausal hormone therapy (MHT) and bone protection sometimes receive denosumab as the anti-fracture agent alongside estrogen-progestogen MHT for symptom control. The combination has not been tested in large fracture-endpoint trials, but DXA substudy data suggest additive bone density gains. Estrogen independently preserves type I and type II muscle fiber cross-sectional area and may offset the muscle-biology uncertainty around RANK-L blockade. The Menopause Society (formerly NAMS) acknowledges MHT as having a favorable effect on lean body mass in early menopause (13).

Monitoring Muscle Function During Denosumab Therapy

Surveillance should be structured, not incidental. A clinician who only asks "how are you feeling?" will miss early sarcopenic progression.

Recommended Assessment Schedule

At the time of each denosumab injection visit (every 6 months), collect:

1. Handgrip dynamometry (dominant hand, best of three trials).
2. Gait speed over a 4-meter or 6-meter corridor.
3. Short Physical Performance Battery (SPPB) score if gait speed is <1.0 m/s.
4. Body weight and, when available, DXA appendicular lean mass index (ALMI; kg/m2).

A drop in handgrip strength of more than 5 kg over 12 months or a gait speed decline below 0.8 m/s should trigger formal physical therapy referral and dietary review. An ALMI below 7.0 kg/m2 in men or 5.5 kg/m2 in women meets the EWGSOP2 threshold for confirmed sarcopenia.

Laboratory Work Relevant to Muscle Health

At least once yearly, check:

• Serum 25-hydroxyvitamin D (target 30 to 50 ng/mL).
• Total and free testosterone in men experiencing unexplained muscle weakness.
• Serum albumin and prealbumin if protein intake is questioned.
• TSH (thyroid dysfunction independently accelerates muscle atrophy).
• Serum creatinine and eGFR (denosumab dose is unchanged in renal impairment, unlike bisphosphonates, but uremia itself drives sarcopenia).

Denosumab Discontinuation and the Rebound Risk to Both Bone and Muscle

Stopping denosumab without transitioning to an oral or IV bisphosphonate produces a sharp rebound in bone resorption markers, beginning approximately 6 months after the missed injection. Vertebral fractures cluster in the 12 months following discontinuation, with case series reporting rates of 2 to 10% in the absence of bridging therapy (14).

The muscle implications of rebound resorption are indirect but real. Rapid bone loss elevates circulating calcium transiently and releases bone-embedded growth factors (TGF-beta, IGF-1), producing a brief but chaotic systemic environment. Patients who stop denosumab without bridging and subsequently fracture often experience prolonged immobility, which is the single fastest driver of muscle atrophy in older adults: bed rest loses approximately 0.5 kg of lean mass per week.

The American Society for Bone and Mineral Research (ASBMR) Task Force recommends transitioning to zoledronic acid 5 mg IV (one or two doses) or alendronate 70 mg weekly (starting 6 months after the last denosumab injection) to prevent rebound resorption (15).

Special Populations: Glucocorticoid-Induced Osteoporosis

Glucocorticoids (GC) suppress RANK-L production but simultaneously impair muscle protein synthesis through direct inhibition of the IGF-1/Akt/mTOR pathway. Patients on prednisone 5 mg/day or more for 3 or more months qualify for fracture-risk assessment and often denosumab therapy under ACR 2022 guidelines (16).

In this population, GC-induced myopathy stacks on top of whatever RANK-L-related muscle biology may occur. The protein target shifts to 1.6 to 2.0 g/kg/day because GC-mediated catabolism is more aggressive. Resistance training sessions may need to stay at the lower end of intensity (50 to 60% 1-RM) to avoid tendon injury, as GC impairs collagen synthesis in tendons even when muscle is the clinical concern.

Practical Patient Counseling Points

Clear instructions improve adherence. At the time of each 6-month injection, the prescribing clinician or nurse practitioner should cover four items:

1. The next injection date (stress it is not optional to delay beyond 7 months).
2. Calcium and vitamin D dosing confirmation.
3. Exercise prescription review or referral update.
4. Dietary protein check-in and, if needed, referral to a registered dietitian.

The Endocrine Society clinical practice guideline on osteoporosis in postmenopausal women states: "We recommend that clinicians counsel all patients receiving pharmacologic osteoporosis therapy about the importance of adequate calcium and vitamin D intake, regular weight-bearing exercise, and fall prevention strategies." (17)

Dr. Serge Ferrari, professor of bone diseases at Geneva University Hospitals and a principal investigator on the FREEDOM Extension, has noted in peer-reviewed commentary that "muscle and bone should be treated as one functional unit, and antiresorptive therapy addresses only half of that unit." That framing reflects the growing consensus that fracture prevention is incomplete without parallel attention to the muscle that must absorb and redirect mechanical load before it reaches bone.